Marfan syndrome is a genetic disorder that affects body’s connective tissues. Connective tissues are made up of proteins, especially fibrilin-1, which are responsible for holding the whole body, i.e. organs, tissues, and cells together. Marfan syndrome is caused by the mutation in FBN1 gene which makes protein fibrilin-1. A defect in the fibrilin protein can cause overgrowth in the bones. Moreover, Marfan syndrome primarily affects the cardiovascular system, skeletal system, skin, and the eyes of humans. The condition is mostly inherited; however, 25% of the time it is a new (de novo) mutation. According to the National Human Genome Research Institute, globally one in every 10,000 to 20,000 individuals develop Marfan syndrome. People with Marfan syndrome are very tall, with long, thin arms and legs, with spider like fingers, referred as arachnodactyly. Other symptoms include myopia, ectopia lentis, glaucoma, retinal detachment, and early cataract formation. Additionally, bone overgrowth, loose joints, curvature of the spine (scoliosis), mitral valve prolapse, aortic dissection, and tricuspid valve prolapse are also observed in affected individuals.
Marfan syndrome is difficult to diagnose because its signs and symptoms can vary from person to person. Diagnosis can be carried out through physical examination, medical history, eye examination, chest X-ray, MRI scan, genetic testing, prenatal testing, and preimplantation genetic testing. The Marfan syndrome cannot be cured, but patients can live long, full life with proper treatment and/or management. There is no medical treatment to reverse the fibrillin abnormality in people with Marfan syndrome. Medications that can decrease the pressure inside the aorta such as beta blockers and angiotensin blockers are mostly prescribed. Beta blockers such as propranolol, metoprolol, and atenolol decrease the strain on the aorta by reducing force of contraction. Angiotensin blockers act primarily by lowering blood pressure, which reduces the stress on artery walls.
Prevalence of Marfan syndrome is more common in infants as it is hereditary. Emergence of new technologies, favorable government initiatives, and availability of favorable reimbursement policies for high-cost therapies are projected to drive the global Marfan syndrome treatment market in the near future. However, high cost of drugs and availability of limited scientific data on the treatment and cure of Marfan syndrome are likely to restrain the global Marfan syndrome treatment market.
The global Marfan syndrome treatment market can be segmented based on treatment type, route of administration, distribution channel, and region. In terms of treatment type, the global market can be categorized into heart treatment such as aortic dilation, drugs treatment such as beta blocker, calcium channel blocker & ACE blocker, surgery, bone and joints treatment, eye treatment, and others. Based on route of administration, the global Marfan syndrome treatment market can be bifurcated into oral and injectable. In terms of distribution channel, the market can be divided into retail pharmacies, hospital pharmacies, and online pharmacies.
Geographically, the global Marfan syndrome treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the largest share of the global market due to high expenditure on health care and easy diagnosis and availability of drugs. Europe is expected to be the second largest market for Marfan syndrome treatment during the forecast period due to drug availability and adoption of new treatment methods. The Marfan syndrome treatment market in Asia Pacific is expected to expand rapidly during the forecast period. Growth of the market in the region can be attributed to rapidly developing health care infrastructure.
Key players operating in the global Marfan syndrome treatment market are Sanis Health, Inc., Novartis Pharmaceuticals Corporation, Baxter Healthcare Corporation, Sanofi, Merck & Co., Inc., ANI Pharmaceuticals, Inc., Validus Pharmaceuticals, Inc., and AstraZeneca, among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.